NCT05963282已完成不适用
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9,870
- 试验地点
- 1
- 主要终点
- Total number of all-cause hospitalizations
研究概览
简要总结
This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction (HFrEF) patients (aged ≥18 years) commencing first-line treatment on either sacubitril/valsartan or commencing or continuing angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blocker (ARB) therapy for HF in the United States (US) using the secondary source of data, Optum Electronic Health Records (EHR).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sacubitril/valsartan cohort:
- •Prescribed sacubitril/valsartan within the identification period.
- •With at least one International Classification of Diseases, 9th Revision (ICD)-9 or 10th Revision (ICD-10) code for diagnosis of HF within 30 days prior to the index date (including index date), that had non-missing sex and year of birth data.
- •Active in the database for 759 days prior to index.
- •With left ventricular ejection fraction (LVEF) ≤ 40% known prior to index day (including index date).
- •That were treated as part of the integrated delivery network (IDN).
- •ACEi/ARB cohort:
- •Prescribed ACEi or ARB within the identification period.
- •With at least one ICD-9 or ICD-10 code for diagnosis of HF within 30 days prior to the index date (including index date), that have non-missing sex and year of birth data.
- •Active in the database for 759 days prior to index.
- •With LVEF ≤ 40% known prior to index day (including index date).
- •That were treated as part of the IDN.
- •Exclusion Criteria
- •Sacubitril/valsartan cohort:
- •That were < 18 years old at index date.
- •That were prescribed sacubitril/valsartan within the baseline period or identification period (whichever was earlier) at any time prior to the index date (excluding).
- •With one or more ICD-9 or ICD-10 codes for diagnosis of HF within the baseline period, excluding the 30 days prior to index in which HF was initially identified (patient should have had no prior history of HF).
- •That were prescribed ACEi/ARB > 2 days before index date, and within 30 days after a HF diagnosis during the identification period (i.e. any patient included in the ACEi/ARB cohort with an earlier index date, regardless of whether LVEF was ≤ 40% or > 40%)
- •With LVEF ≤ 10% as the closest value to index date (including).
- •ACEi/ARB cohort:
- •That were < 18 years old at index date.
- •That were prescribed sacubitril/valsartan within the baseline period or identification period (whichever was earlier) at any time prior to the index date, on the index date, or until ≤ 2 days after the index date.
- •With one or more ICD-9 or ICD-10 codes for diagnosis of HF within the baseline period, excluding the 30 days prior to index in which HF was initially identified (patient should have had no prior history of HF).
- •With LVEF ≤ 10% as the closest value to index date (including).
排除标准
- 未提供
结局指标
主要结局
Total number of all-cause hospitalizations
时间窗: Up to approximately 5 years
次要结局
- Number and proportion of HF-specific inpatient hospitalizations(Up to approximately 5 years)
- Number and proportion of HF-related inpatient hospitalizations(Up to approximately 5 years)
- Dosages and dose changes of sacubitril/valsartan administered(Up to approximately 5 years)
- Numbers and proportions of first and recurrent (1st, 2nd, 3rd, 4th and 5th) all-cause inpatient hospitalizations(Up to approximately 5 years)
- Number and proportion of non-CV inpatient hospitalizations(Up to approximately 5 years)
- Time to first all-cause hospitalization(Up to approximately 5 years)
- Numbers and proportions of first and recurrent (1st, 2nd, 3rd, 4th and 5th) HF-specific inpatient hospitalizations.(Up to approximately 5 years)
- Number and proportion of cardiovascular (CV)-specific inpatient hospitalizations(Up to approximately 5 years)
- Number and proportion of patients with ≥1 implantable cardioverter defibrillator (ICD) insertion during a hospitalization or during an emergency room (ER) visit for both the sacubitril/valsartan and ACEi/ARB cohorts(Up to approximately 5 years)
- Number and proportion of non-HF inpatient hospitalizations(Up to approximately 5 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
Unknown
Retrospective clinical study for comparison of survival between high albumin leakage and low albumin leakage in super high-flux hemodialysisPatients with end-stage kidney disease undergoing hemodialysisJPRN-UMIN000050068others738
已完成
4 期
Comparison of therapeutic efficacy of two different medical treatments and hormone releasing intrauterine device in treatment of heavy uterine bleedingHeavy menstrual bleeding defined by PBAC scoresReproductive Health and Childbirth - Menstruation and menopauseACTRN12612001055897Mine Kiseli66
招募中
3 期
The effect of adding sertraline to dapoxetine in relieving sexual problems in meIRCT20150913024006N5Esfahan University of Medical Sciences50
Unknown
不适用
Efficacy and Safety of Non-resorbable Uveoscleral Implant Versus Absorbable Collagen Matrix in Non-perforating Deep SclerectomyGlaucomaNCT04586738Germans Trias i Pujol Hospital120
尚未招募
2 期
Ayurvedic treatment for pain, swelling and stiffness in all jointsCTRI/2021/03/031630Shree jagadguru gavisidheswara ayurvedic medical college postgraduate studies and research center